Seagen tees up with Dutch I/O outfit, engineers $700M deal for EGFR asset
Amid reports that Merck was going to acquire Seagen, the Seattle company decided to do its own M&A — securing a back-heavy deal.
The antibody-drug conjugate powerhouse announced bright and early Monday that it would be shelling out as much as $700 million to LAVA Therapeutics, a Netherlands-based gamma delta T cell engager biotech, for its EGFR-targeting drug candidate.
The candidate, called LAVA-1223, is in an advanced preclinical stage, LAVA CEO Steve Hurly tells Endpoints News.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.